From novel diagnostics to advanced therapies and evolving cancer policy

This cluster highlights rapid advances in cancer detection and treatment, from promising blood-based diagnostics and refined prostate scoring systems to next‑generation options like mRNA vaccines, TILs, CAR‑T, nanoparticle hyperthermia, and carbon ion therapy. It also captures mixed results and open questions, including the failure of a major multi‑cancer blood test trial and concerns about cancer risk near nuclear plants and long‑term toxicities such as hearing loss in childhood survivors. Alongside clinical guidelines, biosimilars, and targeted therapies across breast, skin, gastric, and blood cancers, policy and industry moves—like new U.S. incentives for childhood cancer drugs and strategic cell‑therapy acquisitions—signal an accelerating but uneven shift toward more personalized, accessible oncology care.